ReviewMolecular medicine reports2026
Genetic and molecular mechanisms of hereditary thoracic aortic aneurysm and dissection (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic aortic aneurysm and dissection (TAAD) is a life‑threatening disease with an insidious onset and a largely elusive pathogenesis. Hereditary TAAD (HTAD) can be classified into syndromic forms, including Marfan syndrome, Loeys‑Dietz syndrome and vascular Ehlers‑Danlos syndrome and non‑syndromic forms, including familial TAAD and bicuspid aortic valve‑associated TAAD. Current evidence suggests that HTAD development shares several core mechanisms, including extracellular matrix disruption, dysregulated transforming growth factor‑β signaling, vascular smooth muscle cell dysfunction and, in the case of bicuspid aortic valve, abnormal hemodynamic stress. The present review summarizes the major genes and molecular pathways involved in HTAD and discusses their contributions to disease progression. Elucidating the underlying mechanisms associated with HTAD may facilitate risk assessment and the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.